ecancer
Avatar

EHA 2021 Highlights on KRd for Lenalidomide-Refractory MM

By ecancer FEATURING Claudio Cerchione
By ecancer FEATURING Claudio Cerchione
86 views
September 2, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Related Content

AUTOPLAY
18:26
William Schaffner

Shingles (Herpes Zoster) Vaccination in Adults: What is the Importan…

16:42
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…

Feat. H. Hashmi
20:19
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …

Feat. A. Paulus
19:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…

Feat. R. Banerjee
12:38
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…

Feat. S. Usmani
14:09
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Multiple Myeloma Highlights and Clinical P…

Feat. H. Hashmi
49:01
Scripps MD Anderson Cancer Center

Current Summary of the Multiple Myeloma Treatment Landscape

Feat. R. Lu
12:35
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Treatment Options for Patients With Myelo…

Feat. C. Cerchione
31:51
Indy Hematology Review

Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…

Feat. K. Anderson
15:01
Patrick Hagen

Treating High-Risk Pts With Early-Relapsed MM

03:17
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Highlights From the International Myeloma S…

Feat. J. Richter
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
20:26
MyCancerHaven

Experts Discuss the Management of Multiple Myeloma at First Relapse

Feat. R. Vij, B. Lipe
10:25
Srinivas Devarakonda

Choosing Appropriate Patients for Treatment With Monoclonal Antibody…

07:37
ASH 2022 Conference Coverage

IKEMA Subgroup Analysis: Isatuximab + Carfilzomib & Dexamethason…

Feat. T. Martin
13:18
Insights from 2023 IMS Annual Meeting

Highlights and Key Takeaways From the 2023 International Myeloma Soc…

Feat. A. Jakubowiak
21:51
Moffitt Cancer Center

State-of-the-Art: Bispecific Antibodies in Myeloma - Which? How? Whe…

Feat. A. Grajales-Cruz
26:46
Samer Al Hadidi

CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…

09:00
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Time to Tailor? Treatment Selection at Firs…

Feat. M. Delforge
12:33
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Minimizing Uncertainty in Multiple Myelom…

Feat. K. Patel